Digital mindfulness app for teens with eczema

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial tests a digital mindfulness meditation app against standard care for adolescents with atopic dermatitis. Participants are aged 13-17 with moderate to severe disease not fully controlled by topical therapy. The study uses validated surveys to measure changes in disease control and well-being over time. It is conducted at Weill Cornell Medicine and Columbia University, involving collaboration between these institutions.

Why it matters

Who can join: the full rules

Inclusion Criteria

* Adolescents age 13-17 years.
* Atopic dermatitis refractory to standard topical treatment including topical steroids or topical calcineurin inhibitors.
* Moderate to severe atopic dermatitis via PO-SCORAD score on enrollment.

Exclusion Criteria

* Started on a biologic agent (i.e. dupxient) within the past 3 months.
* Mild atopic dermatitis via PO-SCORAD score on enrollment.

Where it's running

• Weill Cornell Medicine
  New York, New York, United States Recruiting
• Columbia University Irving Medical Center
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Dana O'Toole, MD — Weill Medical College of Cornell University
• Study coordinator: Dana A O'Toole, MD
• Email: wcmpedsallergy@med.cornell.edu
• Phone: 646-962-3410

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Camoteskimab in adults with moderate-to-severe atopic dermatitis

  This trial tests different doses of camoteskimab versus placebo to see if it helps adults with moderate-to-severe atopic dermatitis who have not fully responded to standard treatments.

  Recruiting at 31 sites Phase 2 Apollo Therapeutics Ltd · Birmingham, Alabama and 84 other locations · NCT07599813

• Low-sodium diet and salt tablets to see if eczema improves

  This study tests whether a low-sodium diet can lessen eczema symptoms in adults with atopic dermatitis, using a cross-over design with sodium tablets and placebo to see if salt intake changes skin sodium and severity.

  Recruiting at 2 sites Phase 4 University of California, San Francisco · San Francisco, California and 1 other locations · NCT07447063

• Soquelitinib for adults with moderate to severe atopic dermatitis

  This 12-week test gives adults with moderate to severe atopic dermatitis daily soquelitinib or a placebo to see if their skin and itch improve and to track side effects.

  Recruiting Phase 2 Corvus Pharmaceuticals, Inc. · South San Francisco, California · NCT07441395

• GX-03 topical treatment for adults with moderate to severe eczema

  This study will test whether applying GX-03, a topical emollient, twice daily for 8 weeks reduces eczema severity and itch in adults with moderate to severe atopic dermatitis compared with a petrolatum-based vehicle.

  Recruiting Phase 2/3 Turn Therapeutics · Irving, Texas · NCT07355075

• Non-Invasive Skin Fluid Biomarkers in Babies with and without Eczema

  This study tests whether a tiny, painless device can safely collect skin interstitial fluid from babies to see if eczema changes immune signals compared with healthy babies.

  Recruiting King's College London · London · NCT07228962

• IMG-007 for adults with moderate-to-severe atopic dermatitis.

  This study will test if different doses of IMG-007 reduce skin inflammation and itching in adults with moderate-to-severe atopic dermatitis compared with a placebo.

  Recruiting at 23 sites Phase 2 Inmagene LLC · Lancaster, California and 29 other locations · NCT07037901

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.